Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
详细信息 查看全文
- 作者：I. Gouin-Thibault ; X. Delavenne ; A. Blanchard ; V. Siguret ; J. E. Salem ; C. Narjoz ; P. Gaussem ; P. Beaune ; C. Funck-Brentano ; M. Azizi ; P. Mismetti and M. A. Loriot
- 刊名：Journal of Thrombosis and Haemostasis
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：15
- 期：2
- 页码：273-283
- 全文大小：336K
- ISSN：1538-7836
文摘
The direct oral anticoagulants (DOACs) dabigatran and rivaroxaban are both substrates of the P-glycoprotein (P-gp) transporter, encoded by the ABCB1 gene. Rivaroxaban is metabolized by cytochrome P450 A4 (CYP3A4). Interindividual variability in DOAC exposure and frequent P-gp-associated drug–drug interactions have been described in patients.